Mediating Role of Myokines in the Dialogue Between Muscle and Bone Tissue in a Population of Healthy Women Aged 20-89 Years

Inclusion Criteria: * Self-reported Caucasian ethnicity (Europe, Middle East, North Africa) only as there is a difference in BMD by ethnicity. * Person affiliated with or benefiting from a social security scheme. * Free, informed consent signed by the participant and the investigator (at the latest on the day of inclusion and before any examination required by the research). Exclusion Criteria: * Fragility fracture defined as a spontaneous or low-kinetic fracture (≤ one fall from height). * Early menopause (\< 40 years), hysterectomy (complete \< 40 years), primary amenorrhea (absence of menstruation before 15 years), current amenorrhea of more than 3 months without contraceptive if the patient is less than 40 years old. * Patients on treatments: prolonged corticosteroid therapy \> 3 months or \> 1 g (cumulative dose). * Immobilization of more than 3 months, less than 12 months old. * Hip fracture in a first-degree relative. Patients with any of the following pathologies affecting bone, muscle or adipose tissue: * Inflammatory bowel disease (IBD: Crohn's disease, ulcerative colitis) and untreated celiac disease. * Renal insufficiency on dialysis or patients with nephrology follow-up. * Known hypercalciuria. * Osteomalacia, rickets, osteogenesis imperfecta. * Osteopathy (Paget's disease, osteopetrosis, etc.). * Chronic inflammatory rheumatism. * Hemopathy, neoplasia. * Hepatic insufficiency or chronic hepatitis. * Endocrinopathy: diabetes, dysthyroidism, hypogonadism, hypercorticism, untreated acromegaly. * Anorexia nervosa. * Hyperparathyroidism (even controlled). * History of digestive surgery (bariatric, gastrectomy, digestive resection other than appendectomy, etc.). * History of organ transplantation. * Chronic infectious disease (HIV, etc.). * Weight loss of more than 10 kg within 6 months. * Paresis, marked lameness or unloading of a limb, or prolonged immobilization of more than one month in the last 12 months. * Patients on treatments that may affect bone mass or body composition: * Biphosphonates (Alendronate (Fosamax® and generics), Risedronate (Actonel® and generics), Zoledronate (Aclasta® and generics). * Teriparatide (Forsteo®). * Denosumab (Prolia®) * Selective estrogen receptor modulators (Clomifene, Tamoxifene, Toremifene, Raloxifene). * Anabolic steroids. * Strontium ranelate. * Carbamazepine. * Phenobarbital. * Immunosuppressants. * Patients on anti-epileptics. * Patients with any of the following abnormalities in the measurement area: * Major deformities of the wrist, hip or vertebrae. * Compression of vertebral bodies, cementoplasty. * Prosthesis, implant (breast, buttock, etc.), foreign body. * Hip paraosteoarthropathy. * Injection of radiological contrast medium, barium enema, nuclear medicine examination within 10 days. * Intensive sport (more than 10 h/week). * Extreme BMI (BMI \< 18, BMI \> 35 kg/m²). * Loss of autonomy. * People with neurodegenerative disorders affecting their ability to give consent. * Pregnant, parturient or breast-feeding women. * Participation in an interventional study involving a drug or medical device or a category 1 RIPH within 3 months prior to inclusion.